Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sean Igelman"'
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 7:719-722
The development of immune checkpoint inhibitors such as programmed cell-death receptor 1 (PD-1) antagonists has rapidly advanced chemotherapy within the last several decades. PD-1 targeted immunotherapy drugs like pembrolizumab, ipilimumab, nivolumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94050f263ace7a59cf21dfeec1268ca2
https://doi.org/10.25251/skin.7.2.11
https://doi.org/10.25251/skin.7.2.11
Autor:
Joshua Eickstaedt, Amy S. Paller, Emily Lund, Morgan Murphrey, Heather Brandling-Bennett, Megan Maurano, Esteban Fernandez Faith, Kristen E. Holland, Erin Ibler, Marilyn G. Liang, Patricia S. Todd, Elaine Siegfried, Sean Igelman, Kelly M. Cordoro, Megha M. Tollefson
Publikováno v:
JAMA Dermatology.
ImportanceTumor necrosis factor α (TNF) inhibitor–induced psoriasiform eruption is well recognized in adults, but few reports document this paradoxical effect in children.ObjectiveTo characterize the clinical features and the clinical time course
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ce397064ccad38203273e8d6de6a91b
https://doi.org/10.1001/jamadermatol.2023.0549
https://doi.org/10.1001/jamadermatol.2023.0549
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 7:640-641
Syringofibroadenoma is a rare adnexal tumor which is derived from the acrosyringial cells of the eccrine ducts. The presentation of this lesion is variable and nonspecific, making the diagnosis, based off presentation alone, difficult. With a wide di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c1c0f9463c6dfc57f739124fb351b7c
https://doi.org/10.25251/skin.7.1.17
https://doi.org/10.25251/skin.7.1.17
Publikováno v:
JAAD Case Reports, Vol 6, Iss 2, Pp 139-140 (2020)
JAAD Case Reports
JAAD Case Reports
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42b481cc08a42399d3cbef7a92ef7b4a
https://doi.org/10.1016/j.jdcr.2019.12.002
https://doi.org/10.1016/j.jdcr.2019.12.002
Autor:
Lara Wine Lee, Eric S. Armbrecht, Sean Igelman, Umar A. Sheikh, Anna Smith, Avni Patel, Elaine C. Siegfried, Leslie Castelo-Soccio, Richard J. Antaya, Lisa M. Arkin, Nicole W. Kittler, Sonal Shah, M. Carmen Fraile-Alonso, Anastasia O. Kurta, Moise L. Levy, James R. Treat, Ashley McWilliams, Lucia Z. Diaz, Douglas W. Kress, Stephanie R. Jackson Cullison, William D. Boothe
Publikováno v:
Journal of the American Academy of Dermatology. 82(2)
Background Atopic dermatitis (AD) is a common, chronic type 2 inflammatory skin disease, typically starting in infancy, with increased risk for subsequent extracutaneous atopic morbidities. Dupilumab is the first biologic agent targeting type 2 infla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc5e1fc21a930e9bfb801f59a789caab
https://pubmed.ncbi.nlm.nih.gov/31606479
https://pubmed.ncbi.nlm.nih.gov/31606479
Autor:
Kelly M. Cordoro, Jennifer C. Jaworsk, Moise L. Levy, Richard J. Antaya, Sean Igelman, Elaine C. Siegfried, Lawrence F. Eichenfield, Amy S. Paller
Publikováno v:
Pediatric dermatology. 36(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40323e8d5d5cd76fff10edbaf75e2976
https://pubmed.ncbi.nlm.nih.gov/32981159
https://pubmed.ncbi.nlm.nih.gov/32981159